Eton Pharmaceuticals, Inc. Operating Cash Flow
Eton Pharmaceuticals, Inc. (ETON) reported Operating Cash Flow of $14.66 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- Eton Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $7.25M, a 8.85% decline year-over-year.
- Eton Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was $7.41M, a 254.31% increase year-over-year.
- Eton Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$11.55M.
- Eton Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $12.03M, a 307.38% increase year-over-year.
- Eton Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2025 was $10.52M, a 986.07% increase from fiscal 2024.
- Eton Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2024 was $969.00K, a 85.78% decline from fiscal 2023.
- Eton Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2023 was $6.82M, a 41.36% increase from fiscal 2022.
- Eton Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2022 was $4.82M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 5 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 8 month | Net Cash Provided by (Used in) Operating Activities 8 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $7.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $14.66M 10-Q · filed 2026-08-13 | $3.11M derived: sum of 3 quarters · filed 2026-08-13 | $15.13M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | $7.41M 10-Q · filed 2026-05-14 | -$4.15M derived: sum of 2 quarters · filed 2026-05-14 | $7.88M derived: sum of 3 quarters · filed 2026-05-14 | $15.84M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-12-31 | -$11.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $475.00K derived: sum of 2 quarters · filed 2026-03-19 | $8.43M derived: sum of 3 quarters · filed 2026-08-13 | $10.52M 10-K · filed 2026-03-19 | |||
| 2025-09-30 | $12.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $19.98M derived: sum of 2 quarters · filed 2026-08-13 | $22.07M 10-Q · filed 2025-11-06 | $21.31M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-06-30 | $7.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $10.05M 10-Q · filed 2026-08-13 | $9.28M derived: sum of 3 quarters · filed 2026-08-13 | $12.24M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-03-31 | $2.09M 10-Q · filed 2026-05-14 | $1.32M derived: sum of 2 quarters · filed 2026-05-14 | $4.28M derived: sum of 3 quarters · filed 2026-05-14 | $5.53M derived: sum of 4 quarters · filed 2026-05-14 | |||
| 2024-12-31 | -$765.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $2.19M derived: sum of 2 quarters · filed 2026-03-19 | $3.44M derived: sum of 3 quarters · filed 2026-03-19 | $969.00K 10-K · filed 2026-03-19 | |||
| 2024-09-30 | $2.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.21M derived: sum of 2 quarters · filed 2025-11-06 | $1.73M 10-Q · filed 2025-11-06 | $2.12M derived: sum of 4 quarters · filed 2026-03-19 | |||
| 2024-06-30 | $1.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$1.22M 10-Q · filed 2025-08-07 | -$831.00K derived: sum of 3 quarters · filed 2026-03-19 | $42.00K derived: sum of 4 quarters · filed 2026-03-19 | |||
| 2024-03-31 | -$2.47M 10-Q · filed 2025-05-13 | -$2.09M derived: sum of 2 quarters · filed 2026-03-19 | -$1.21M derived: sum of 3 quarters · filed 2026-03-19 | $5.89M derived: sum of 4 quarters · filed 2026-03-19 | |||
| 2023-12-31 | $387.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $1.26M derived: sum of 2 quarters · filed 2026-03-19 | $8.36M derived: sum of 3 quarters · filed 2026-03-19 | $6.82M 10-K · filed 2026-03-19 | |||
| 2023-09-30 | $873.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $7.98M derived: sum of 2 quarters · filed 2024-11-12 | $6.43M 10-Q · filed 2024-11-12 | $9.27M derived: sum of 4 quarters · filed 2025-03-18 | |||
| 2023-06-30 | $7.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $5.55M 10-Q · filed 2024-08-08 | $8.39M derived: sum of 3 quarters · filed 2025-03-18 | $6.69M derived: sum of 4 quarters · filed 2025-03-18 | |||
| 2023-03-31 | -$1.55M 10-Q · filed 2024-05-09 | $1.29M derived: sum of 2 quarters · filed 2025-03-18 | -$411.00K derived: sum of 3 quarters · filed 2025-03-18 | $2.05M derived: sum of 4 quarters · filed 2025-03-18 | |||
| 2022-12-31 | $2.84M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $1.14M derived: sum of 2 quarters · filed 2025-03-18 | $3.60M derived: sum of 3 quarters · filed 2025-03-18 | $4.82M 10-K · filed 2025-03-18 | |||
| 2022-09-30 | -$1.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $758.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.98M 10-Q · filed 2023-11-09 | -$3.14M derived: sum of 4 quarters · filed 2024-03-14 | |||
| 2022-06-30 | $2.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $3.68M 10-Q · filed 2023-08-10 | -$1.43M derived: sum of 3 quarters · filed 2024-03-14 | -$4.38M derived: sum of 4 quarters · filed 2024-03-14 | |||
| 2022-03-31 | $1.22M 10-Q · filed 2023-05-11 | -$3.89M derived: sum of 2 quarters · filed 2024-03-14 | -$6.84M derived: sum of 3 quarters · filed 2024-03-14 | -$7.21M derived: sum of 4 quarters · filed 2024-03-14 | |||
| 2021-12-31 | -$5.12M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$8.07M derived: sum of 2 quarters · filed 2024-03-14 | -$8.44M derived: sum of 3 quarters · filed 2024-03-14 | -$4.72M 10-K · filed 2024-03-14 | |||
| 2021-09-30 | -$2.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$3.32M derived: sum of 2 quarters · filed 2022-11-10 | $396.00K 10-Q · filed 2022-11-10 | -$6.79M derived: sum of 4 quarters · filed 2023-03-16 | |||
| 2021-06-30 | -$369.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $3.35M 10-Q · filed 2022-08-11 | -$3.84M derived: sum of 3 quarters · filed 2023-03-16 | -$8.93M derived: sum of 4 quarters · filed 2023-03-16 | |||
| 2021-03-31 | $3.71M 10-Q · filed 2022-05-12 | -$3.47M derived: sum of 2 quarters · filed 2023-03-16 | -$8.56M derived: sum of 3 quarters · filed 2023-03-16 | -$11.41M derived: sum of 4 quarters · filed 2023-03-16 | |||
| 2020-12-31 | -$7.18M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$12.28M derived: sum of 2 quarters · filed 2023-03-16 | -$15.13M derived: sum of 3 quarters · filed 2023-03-16 | -$22.35M 10-K · filed 2023-03-16 | |||
| 2020-09-30 | -$5.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-16 | -$7.95M derived: sum of 2 quarters · filed 2021-11-16 | -$15.16M 10-Q · filed 2021-11-16 | -$19.01M derived: sum of 4 quarters · filed 2022-03-16 | |||
| 2020-06-30 | -$2.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$10.07M 10-Q · filed 2021-08-16 | -$13.92M derived: sum of 3 quarters · filed 2022-03-16 | -$17.13M derived: sum of 4 quarters · filed 2022-03-16 | |||
| 2020-03-31 | -$7.22M 10-Q · filed 2021-05-13 | -$11.06M derived: sum of 2 quarters · filed 2022-03-16 | -$14.28M derived: sum of 3 quarters · filed 2022-03-16 | -$18.48M derived: sum of 4 quarters · filed 2022-03-16 | |||
| 2019-12-31 | -$3.85M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | -$7.06M derived: sum of 2 quarters · filed 2022-03-16 | -$11.26M derived: sum of 3 quarters · filed 2022-03-16 | -$18.03M 10-K · filed 2022-03-16 | |||
| 2019-09-30 | -$3.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$7.41M derived: sum of 2 quarters · filed 2020-11-12 | -$14.18M 10-Q · filed 2020-11-12 | -$15.95M derived: sum of 4 quarters · filed 2021-03-16 | |||
| 2019-06-30 | -$4.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | -$10.96M 10-Q · filed 2020-08-12 | -$12.74M derived: sum of 3 quarters · filed 2021-03-16 | -$15.03M derived: sum of 4 quarters · filed 2021-03-16 | |||
| 2019-03-31 | -$6.77M 10-Q · filed 2020-05-14 | -$8.54M derived: sum of 2 quarters · filed 2021-03-16 | -$10.83M derived: sum of 3 quarters · filed 2021-03-16 | -$13.06M derived: sum of 4 quarters · filed 2021-03-16 | |||
| 2018-12-31 | -$1.77M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | -$4.07M derived: sum of 2 quarters · filed 2021-03-16 | -$6.29M derived: sum of 3 quarters · filed 2021-03-16 | -$8.14M 10-K · filed 2021-03-16 | |||
| 2018-09-30 | -$2.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | -$4.52M derived: sum of 2 quarters · filed 2019-11-14 | -$6.37M 10-Q · filed 2019-11-14 | ||||
| 2018-06-30 | -$2.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$4.08M 10-Q · filed 2019-08-06 | |||||
| 2018-03-31 | -$1.85M 10-Q · filed 2019-05-07 | ||||||
| 2017-12-31 | -$4.72M 10-K · filed 2020-03-05 | $4.72M 10-Q · filed 2018-12-20 | |||||
| 2017-09-30 | -$3.65M 10-Q · filed 2018-12-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |